Summary of key efficacy endpoints.

<p>CI, confidence interval; EOTR, end-of-treatment response; eRVR, extended rapid virologic response; mITT, modified intent-to-treat; RBV, ribavirin; RVR, rapid virologic response; SVR12, sustained virologic response at week 12 post-treatment follow-up; TVR, telaprevir.</p

Baseline demographic and disease characteristics.

<p>HCV, hepatitis C virus; <i>IL28B</i>, interleukin 28B; RBV, ribavirin; TVR, telaprevir.</p

Subgroup analysis for SVR12.

<p>CI, confidence interval; HCV, hepatitis C virus; <i>IL28B</i>, interleukin 28B; RBV, ribavirin; SVR12, sustained virologic response at week 12 post-treatment follow-up; TVR, telaprevir.</p

Patient disposition and reasons for discontinuation.

<p>RBV, ribavirin; TVR, telaprevir.</p

On-treatment safety.

<p>AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; RBV, ribavirin; TVR, telaprevir.</p